期刊文献+

谷胱甘肽治疗帕金森病30例临床观察 被引量:5

An observation of 30 cases of parkinson's disease treated with glutathiono
下载PDF
导出
摘要 目的 探讨还原型谷胱甘肽 (古拉定 ,GLT)对帕金森病人治疗效果 ,观察GLT治疗后病人血超氧化物歧化酶 (SOD)、谷胱甘肽过氧化酶 (GSH Px)、丙二醛 (MDA)水平的变化。方法 选择 30例临床未治疗或服用美多巴因副反应被迫减药病人 ,应用GLT进行治疗 ,治疗前后行血SOD、GSH PX、MDA测定 ,并设立对照组、正常人组比较 ;治疗、Px对照组进行了治疗前后H Y分级及Webster评分。结果 治疗组和正常人组比较 ,血SOD、GSH Px显著减低 (P <0 0 1) ,MDA显著增高 (P <0 0 1) ;GLT治疗后 ,SOD、GSH Px值较治疗前明显升高 (P <0 0 5、P <0 0 1) ,MDA值下降 (P <0 0 5 ) ,而对照组改变不明显。治疗前后评分 ,治疗后临床症状有显著改善 (P <0 0 1) ,与对照组比较 ,两组有显著差异 (P <0 0 1)。结论 GLT对PD病人有较显著治疗作用。 AIM\ To inavestigate the efficacy of reduced glutathione (GLT) on patients of Parkinson's disease and the changes in their blood superoxide dismutase (SOD), glutathione peroxidase (GSH Px), and malodialdehyde after the GLT treatment. METHODS\ 30 clinical cases were picked up for GLT treatment who were to be treated or had had to take redused dosage of L dioxyphenylalanino because of unwanted effects. Their blood SOD, GSH Px and MDA were odtermined before and after the treatment. A control group and a normal group were set up for comparison. The GLT group and the control group were made H Y grading and Webster evaluation. RESULT\ Compared with the normal group, the GLT group had clearly lowered blood SOD, GSH Px ( P<0 01 ) and increased MDA ( P<0 01 ). After the GLT treatment,their SOD, GSH Px were clearly higher than before( P<0 05,P<0 01) while their MDA dropped ( P<0 05 ). The control group did not show obvious changes. The grading revealed that after the treatment the clinical signs in the GLT group were noticeably improved. In comparison with the control group, there was a clear differonce( P< 0 01). CONCLUSION\ GLT has a noticeable efficacy on patients of Parkinson's disease.
出处 《安徽医药》 CAS 2003年第1期22-24,共3页 Anhui Medical and Pharmaceutical Journal
  • 相关文献

参考文献8

  • 1[1]C.W. Olanow. MD. FRCP(C) Oxidation reactions in Parkinson′s disease Neurology 1990;40(Suppl 3):32~5
  • 2[2]Riederer P, Sofic E, Rausch WD et al. Transition metals ferritinglutathione and ascorbic acid in parkinsonian brain. J Neurochem, 1989;52;515~20
  • 3[3]Dexter DT. wells FR, Lees AJ et al. Increased nigraliron contentand alterations in other metal ions courring in brain in Parkinson′sdisease. J Neurochem, 1989;89(6): 1830~6
  • 4[4]Jenner P. Altered mitochondrial function. iron metalolim and glutathione levels in Parkinson's disease. Acta neruol Scand, 1993 ;87(Suppl): 146
  • 5[5]Parkinson′s Study Group. DATATOP: A multicenter clinical trial in early Parkinson′s disease. Arch Neurol, 1989 ;46:1052~60
  • 6[6]Mithofer K, Sandy MS, Smith MTet al. Mitochondrial poisonscause depletion of reduced glutathione in isolated hepatacytes. Arch Biochem Biophys, 1992 ;292 : 132~6
  • 7[7]Offen D, I ziv H. sternin et al. Preventio of Dopamineinuced cell Death by Thiod anvioxidants: Possible implications for treatment of parkinosn′s deasese experimental, Neurology, 141(1996) :32~ 9
  • 8[8]Sechi G, Deledda MG, Bua G et al. Reduced intravenous glutathi one in the treatment of early Prakinson′s disease, Prog. neuro Psychopharmacol,Biol. Psychiatry, 20(1996) : 1159~70

同被引文献65

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部